Table 4 Comparisons of prognostic factors of 14-day mortality between surviving and non-surviving patients with candidemia
| Survivor N = 57 (%) | Non-survivor N = 13 (%) | p | Adjusted ORs (95% CI) | p | |
|---|---|---|---|---|---|
| Age (mean ± SD) | 65.81 ± 13.361 | 72.46 ± 18.715 | 0.959 | ||
| Sex | |||||
| Female | 27 (47.4) | 3 (23.1) | 0.110 | ||
| Male | 30 (57.1) | 10 (76.9) | |||
| Co-morbidities | |||||
| MaCabe classification | 0.163 | ||||
| Non-fatal | 12 (21.2) | 1 (7.7) | |||
| Ultimately fatal | 43 (75.4) | 10 (76.9) | |||
| Rapidly fatal | 2 (3.5) | 2 (15.4) | |||
| Severity of infection | |||||
| Pitt bacteremia score (median, IQR) | 0 (0.0–2.0) | 4.0 (1.0–5.0) | < 0.001 | 1.187 (0.890–1.584) | 0.244 |
| Septic shock | 10 (17.5) | 8 (61.5) | 0.003 | 7.635 (1.159–50.290) | 0.035 |
| Candia colonization | 15 (26.3) | 4 (30.8) | 0.739 | ||
| Candida score ≥ 3 | 11 (19.3) | 6 (46.2) | 0.042 | 0.900 (0.225–3.609) | 0.882 |
| DNI_D1, % | 3.4 (2.2–5.3) | 7.4 (4.0–22.0) | 0.002 | 1.156 (1.039–1.287) | 0.008 |
| DNI_48, % | 2.0 (0.5–2.9) | 6.1 (2.1–14.4) | 0.015 | 1.226 (1.007–1.494) | 0.043 |
| Leukocytes, 103/uL (mean ± SD) | 10,831.58 ± 6010.190 | 10,931 ± 7311.871 | 0.139 | ||
| CRP (median, IQR) | 66.0 (39.0–145.0) | 115.5 (84.2–136.0) | 0.036 | 1.003 (0.996–1.009) | 0.412 |
| Procalcitonin (median, IQR) | 0.47 (0.2–1.9) | 1.0 (0.38–2.09) | 0.303 | ||
| Time to positive, hours, (median, IQR) | 48.0 (34.0–72.0) | 31.0 (26.5–53.0) | 0.066 | ||
| Time to antifungal therapy, hours (median, IQR) | 60 (42.0–96.0) | 36 (12.5–42.0) | 0.013 | 0.968 (0.933–1.004) | 0.079 |
| Duration of Clear- up, days, (median, IQR) | 5 (3.0–9.5) | 4.5 (4.0–5.0) | 0.638 | ||
